Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00027716 · ClinicalTrials.gov registry record · Phase 2
Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma
A Phase 2 study of Sarcoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Study locations
NCT00027716: Completed Phase 2 study of Sarcoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00027716 is a Phase 2 study of Sarcoma that has completed, run by Memorial Sloan Kettering Cancer Center. The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00027716, a Phase 2 study of Sarcoma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6
- Study locations
Study Summary
RATIONALE: Bortezomib may stop the growth of cancer by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who have advanced or metastatic sarcoma.
Conditions Studied
Interventions
- DRUG bortezomib
Study Locations (6)
New York
- Memorial Sloan-Kettering Cancer Center - New York
- University of Chicago Cancer Research Center - New York
- Albert Einstein College of Medicine - The Bronx
Colorado
- University of Colorado Cancer Center at University of Colorado Health Sciences Center - Aurora
Massachusetts
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute - Boston
Pennsylvania
- Abramson Cancer Center at University of Pennsylvania Medical Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-10 |
| Est. Completion | 2004-05 |
| Phase | Phase 2 |
What the finished NCT00027716 record still lists
NCT00027716 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which bortezomib is the first listed.
NCT00027716 lists 6 locations in 4 states (New York, Colorado, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT00027716 about?
NCT00027716 is a clinical study titled "Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma". RATIONALE: Bortezomib may stop the growth of cancer by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who have advanced or metastatic sarcoma.
What is the current status of trial NCT00027716?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-10. Estimated completion is 2004-05.
What conditions does trial NCT00027716 study?
This clinical trial studies the following conditions: Sarcoma.
What interventions are being tested in trial NCT00027716?
The interventions under investigation include: bortezomib (DRUG).
Who is sponsoring clinical trial NCT00027716?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00027716 being conducted?
This trial has 6 study locations across Colorado, Massachusetts, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RECRUITING · Phase 2
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
RECRUITING · Phase 2
-
Fluorescent Intra-operative Tumor Margin Examination
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia